Rheumatoid Arthritis

Despite EULAR recommendations encouraging the tapering of glucocorticoids and the rapidly expanding treatment options for patients with rheumatoid arthritis, glucocorticoids are still commonly prescribed to reduce inflammation and manage disease activity.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, share final thoughts and takeaways on the treatment of rheumatoid arthritis in the community setting.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, review the integration of precision medicine into the management of rheumatoid arthritis.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, discuss barriers to rheumatoid arthritis (RA) treatment selection such as insurance access.

Disease-dependent factors, such as a history of adverse reactions to bio-originators and disease activity, influenced patients' acceptance of switching from a biologic to a biosimilar.

Results of the study, which focused on patient-reported outcomes in addition to clinical measurements, mirror findings from other large-scale studies evaluating the safety and efficacy of biosimilars in patients with rheumatoid arthritis.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine share their thoughts on how MSRC test results impact the treatment selection for patients with RA.

Experts in rheumatology review the molecular signature response classifier (MSRC) test for use in guiding RA treatment selection.

At the 6-month mark, there were no significant differences between the treatment groups regarding composite score-defined remission.

Nehad Soloman, MD, leads a discussion about precision medicine in the treatment arsenal for RA.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, discuss American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) recommendations regarding appropriate timing when changing therapies in managing RA.

Rheumatology specialists review factors in switching a patient with RA to a different treatment, including timing, efficacy assessment, and barriers.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, examine potential risks in continuing a patient on an ineffective treatment in RA.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine share insights on how to measure treatment efficacy in the management of RA.

Rheumatology experts discuss the potential roadblocks to treatment of RA, such as insurance access.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levine, MD, review how the increase in treatment options for RA has led to a trial-and-error approach to treatment.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine describe the treatment path from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to biologic or targeted disease-modifying antirheumatic drugs (b/tsDMARDs) for a typical rheumatoid arthritis (RA) patient.

The time of flare was significantly shorter in the placebo group compared to the baricitinib.

For safety, the proportions of patients with serious treatment-emergent adverse events in the second treatment period were similar between the treatment groups.

The results show 88.1% of patients with rheumatoid arthritis in the study developed humoral immunogenicity.

A post hoc subgroup analysis compared TNFi-IR patients receiving upadacitinib 15 mg once daily in 3 Phase 3 clinical trials: SELECT-BEOYND, SELECT-CHOICE, and SELECT-COMPARE.

The median time-to-remission was longer for women compared to men.

The results show improvements in RAPID3, pain, fatigue, and morning stiffness at weeks 8 and 12 among patients treated with upadacitinib.

In data presented during ACR, investigators find peresolimab could be an effective treatment for adult patients with rheumatoid arthritis.

The sixth indication for the JAK inhbitior from AbbVie makes it the first in class approved for both nr-axSpA and ankylosing spondylitis.

The FDA approved risankizumab in June for adult patients with Crohn’s disease, representing the first IL-23 treatment to be approved for this patient population.

A high percentage of pediatric patients with JIA do not achieve inactive disease during the first 2 years following diagnosis.

Take a few minutes to check out Rheumatology Network's top expert interviews from Q2 2022.